Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : The thread of life -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (772)	8/4/2005 11:02:12 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 1336

"Today Fisher entered into a definitive agreement to acquire privately held Cellomics, Inc. for approximately $49 million in cash. Cellomics, with 2004 revenues of approximately $13 million, is a worldwide leader in the high-content-screening segment of the cellular-analysis market. The addition of Cellomics will build on Fisher's offering of drug-discovery solutions in the life-science marketplace, enabling researchers to accelerate the process of developing new medicines. In connection with this acquisition, Fisher and Carl Zeiss Jena GmbH, Cellomics' largest shareholder, agreed to closely collaborate in the high-content-screening field going forward." genomeweb.com I had a vague notion that stuff like this (or Tissueinformatics, if it is worth anything) would be useful to an outfit like GLGC--with their large bank of tissue samples and such... I mentioned it on one of the yahoo threads, and the idea was immediately dismissed 'tissueinfomatics has been written down' that is, the value has been written off the books. I am no accountant, but simply writing something off doesn't make it truly worthless in my mind. I know I am stating the obvious...repeatedly. burrillandco.com Also from the Burrill website "The uniqueness of Icoria’s proprietary systems biology platform is a direct benefit of its leadership role in metabolomics and its ability to digitally measure tissue phenotypes, which was made possible through the acquisition of TissueInformatics.Inc" It may very well be that there is no value in Icoria, or Tissueinformatics. In that case, you were snookered at $5 4 3 2 1....but at least I did not overpay, and if icoria goes from a marketcap of $7m to zero, so be it.